Related Experiment Video

Updated: Jul 6, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

V Labi1, F Grespi, F Baumgartner

  • 1Division of Developmental Immunology, Department of Biocenter, Innsbruck Medical University, Innsbruck, Austria.

Cell Death and Differentiation
|March 29, 2008
PubMed

Insights

Novel small molecule drugs directly activate apoptosis pathways in tumor cells. These BH3 mimetics offer a promising anticancer therapy approach, independent of p53 or Bcl-2 status.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Current anticancer therapies have limitations.
  • The Bcl-2 protein family regulates apoptosis and mitochondrial integrity.
  • BH3-only proteins can disrupt mitochondrial integrity to induce cell death.

Purpose of the Study:

  • To review the function of BH3-only proteins in cell death signaling.
  • To explore novel anticancer strategies targeting the Bcl-2 pathway.
  • To define the properties of BH3 mimetics as potential anticancer agents.

Main Methods:

  • Literature review of BH3-only protein function.
  • Analysis of molecular mechanisms in apoptosis.
  • Discussion of BH3 mimetic drug development.

Main Results:

  • BH3-only proteins play crucial roles in tumor suppression.
  • BH3 mimetics can induce apoptosis in cancer cells.
  • These agents may bypass resistance mechanisms related to p53 or Bcl-2.

Conclusions:

  • Directly targeting the Bcl-2-regulated apoptosis pathway is a promising therapeutic strategy.
  • BH3 mimetics represent a novel class of anticancer agents.
  • Further understanding of BH3-only proteins is essential for clinical implementation.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...